DuoStim策略在PGT-A周期中的随机非劣效性试验
这项随机对照非劣效性试验在西班牙IVI马德里中心于2017年6月至2020年12月纳入80例38岁及以上预后欠佳、接受PGT-A周期的患者,盲法随机分为对照组39例(连续两个周期常规卵巢刺激)和DuoStim组41例(双刺激策略)。主要结局为每组整倍体率,次要结局为获得整倍体胚胎所需时间及主要周期结局。结果显示两组整倍体率无显著差异,但DuoStim组获得整倍体囊胚的平均天数显著更短。
要点
- 对照组与DuoStim组的整倍体率按随机患者(ITT)分别为16.1%与22.7%(P=0.371),无显著差异。
- 按治疗患者计算的整倍体率对照组为39.0%,DuoStim组为45.7%。
- 获得整倍体囊胚的平均天数对照组为44.1±2.0天,DuoStim组为23.3±2.8天(P<0.001),DuoStim组更短。
核心结论
- 在预后欠佳、接受PGT-A周期的患者中,DuoStim策略维持与连续两个常规卵巢刺激周期相似的整倍体率,同时缩短获得整倍体囊胚所需时间。
研究设计与样本
- 随机对照非劣效性试验,在IVI马德里中心于2017年6月至2020年12月开展,纳入80例38岁及以上预后欠佳、接受PGT-A周期的患者。
- 患者盲法随机分为对照组39例(连续两个周期卵巢刺激)和DuoStim组41例(双刺激策略)。
- 主要结局为每组整倍体率,次要结局为获得整倍体胚胎所需时间及主要周期结局。
主要发现
- 两组基线特征相似。
- 对照组与DuoStim组的平均刺激天数分别为21.3±1.6天与23.0±1.4天(P=0.10),无显著差异。
- 对照组与DuoStim组的总促性腺激素用量分别为4005±450与4245±430(P=0.43),无显著差异。
- 对照组与DuoStim组的MII卵母细胞数分别为8.7±1.8与6.8±1.7(P=0.15),无显著差异。
- 对照组与DuoStim组获得的整倍体胚胎数分别为0.8±0.4与0.6±0.4(P=0.45),无显著差异。
临床怎么用
- 作者认为,在预后欠佳、接受PGT-A周期的患者中采用DuoStim策略可维持相似的整倍体率,同时缩短获得整倍体囊胚所需时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Is the DuoStim strategy an effective alternative to two conventional ovarian stimulation cycles in poor-prognosis patients undergoing preimplantation genetic testing for aneuploidies (PGT-A) to improve euploidy rates and obtain the first euploid embryo in less time? DESIGN: This randomized controlled trial was performed at IVI Madrid between June 2017 and December 2020 and included 80 patients with a suboptimal profile aged 38 or older undergoing PGT-A cycles. Patients were blindly randomized into two groups: 39 women underwent two ovarian stimulations in consecutive cycles (control group), whereas the double stimulation strategy was applied to 41 women (DuoStim group). The main outcome was the euploidy rate in each group. The secondary outcomes were the time it took to obtain a euploid embryo and the main cycle outcomes. RESULTS: The baseline characteristics of the patients were similar. No differences were found between the control group and the DuoStim group in the mean days of stimulation (21.3 ± 1.6 versus 23.0 ± 1.4, P = 0.10), total gonadotrophins (4005 ± 450 versus 4245 ± 430, P = 0.43), metaphase II oocytes (8.7 ± 1.8 versus 6.8 ± 1.7, P = 0.15) or euploid embryos obtained (0.8 ± 0.4 versus 0.6 ± 0.4, P = 0.45). The euploid rate per randomized patient (ITT) was 16.1% in the control group versus 22.7% in the DuoStim group, with P-values of 0.371, and the euploidy rate per patient treated was 39.0% versus 45.7% in the control versus DuoStim groups. However, there was a significant difference in the average number of days it took to obtain a euploid blastocyst, favouring the DuoStim group (44.1 ± 2.0 versus 23.3 ± 2.8, P < 0.001). CONCLUSIONS: The use of the DuoStim strategy in poor-prognosis patients undergoing PGT-A cycles maintains a similar euploidy rate while reducing the time required to obtain a euploid blastocyst.
引用
- Cerrillo M, Cecchino GN, Toribio M, et al. A randomized, non-inferiority trial on the DuoStim strategy in PGT-A cycles. Reprod Biomed Online. 2022. PMID: 36567150. doi:10.1016/j.rbmo.2022.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。